AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AGENT-797’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGENT-797 is under development for the treatment of moderate to severe acute respiratory syndrome due to COVID-19 and solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, non-small cell lung cancer, prostate cancer, relapsed/refractory multiple myeloma, head and neck squamous cell carcinoma, hepatocellular cancer, graft versus host disease and metastatic melanoma. The drug candidate comprises of allogenic invariant natural killer T-cells (iNKT). It is administered through intravenous route.
MiNK Therapeutics overview
MiNK Therapeutics is a biopharmaceutical company. The company develops and commercializes allogeneic, invariant natural killer T cell therapies for the treatment of cancer. MiNK Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of AGENT-797’s drug-specific PTSR and LoA scores, buy the report here.